Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration in Subjects From 16 to 65 Years With Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized Who Completed in a Previous Study

NCT00367432 is registered in ClinicalTrials.gov with UCB Japan Co. Ltd. as lead sponsor.

NCT NCT00367432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00367432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration in Subjects From 16 to 65 Years With Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized Who Completed in a Previous Study
Lead sponsor
UCB Japan Co. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2006
Completion date
December 31, 2010
Enrollment
398 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsies, partial